DeepMed Research

BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

Intrathecal Mafosfamide

Phase 1

Completed

Conditions: Malignant Meningeal Neoplasms

First Posted Date: 2003-06-18

Last Posted Date: 2020-03-04

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 65

Registration Number: NCT00062881

Locations: 🇺🇸
Children'sHospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital and Medical Center, Seattle, Washington, United States
🇺🇸
Pediatric Branch, National Cancer Institute, Bethesda, Maryland, United States

and more 6 locations

LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

Phase 1

Completed

Conditions: Hodgkin Disease
Lymphoepithelioma
Leiomyosarcoma
Non Hodgkin Lymphoma

Interventions: Biological: LMP1/2 CTLs (ALCI - Group C)
Biological: LMP1/2 CTLs (ALCI - Group B)
Biological: LMP1/2 CTLs (ALCI - Expansion Group B)
Biological: LMP1/2 CTLs (ALCI - Expansion Group C)
Biological: LMP1/2 CTLs (ALCI - Expansion - Group A)
Biological: LMP1/2 CTLs (ALCI - Group A)
Biological: LMP2 CTLs (ALSCER - Group A)
Biological: LMP2 CTLs (ALSCER - Group C)
Biological: LMP2 CTLs (ALSCER - Group B)

First Posted Date: 2003-06-18

Last Posted Date: 2020-06-09

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 74

Registration Number: NCT00062868

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Procedure: Skin Biopsy
Genetic: Gene Modified Neuroblastoma Cells

First Posted Date: 2003-06-18

Last Posted Date: 2012-10-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 9

Registration Number: NCT00062855

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Study of Irinotecan on a Weekly Schedule in Children

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Irinotecan

First Posted Date: 2003-06-18

Last Posted Date: 2020-03-04

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 23

Registration Number: NCT00062842

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Valacyclovir in Immunocompromised Children

Phase 1

Completed

Conditions: Shingles
Bone Marrow Transplantation

Interventions: Drug: Valacyclovir

First Posted Date: 2003-04-30

Last Posted Date: 2020-03-04

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 37

Registration Number: NCT00059592

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

Phase 1

Terminated

Conditions: Hodgkin Disease
Non-Hodgkins Lymphoma

Interventions: Drug: Infusion of EBV Specific Cytotoxic T-Lymphocytes

First Posted Date: 2003-04-15

Last Posted Date: 2012-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 5

Registration Number: NCT00058773

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells

Phase 1

Completed

Conditions: Chronic Lymphocytic B-Leukemia

First Posted Date: 2003-04-15

Last Posted Date: 2012-05-23

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 9

Registration Number: NCT00058786

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States

Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts

Phase 1

Completed

Conditions: Epstein-Barr Virus Infections

Interventions: Biological: EBV specific T cells

First Posted Date: 2003-04-15

Last Posted Date: 2015-01-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 69

Registration Number: NCT00058812

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Stem Cell Transplant for Hematologic Diseases

Phase 1

Terminated

Conditions: Hematologic Malignancies

Interventions: Biological: Campath 1H
Drug: Fludarabine
Procedure: Stem Cell Transplant
Radiation: Total Body Irradiation (TBI)
Drug: FK506 (Tacrolimus) or Cyclosporine

First Posted Date: 2003-04-15

Last Posted Date: 2016-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 27

Registration Number: NCT00058825

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: Dose Level 3
Biological: Dose Level 1
Biological: Dose Level 2

First Posted Date: 2003-04-15

Last Posted Date: 2020-01-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 11

Registration Number: NCT00058799

Locations: 🇺🇸
Texas Children's Hospital GCRC, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy